SNY - Sanofi

NYSE - NYSE Delayed Price. Currency in USD
43.70
+0.46 (+1.06%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close43.24
Open43.36
Bid0.00 x 0
Ask0.00 x 0
Day's Range43.30 - 43.79
52 Week Range38.45 - 50.65
Volume1,483,914
Avg. Volume1,233,742
Market Cap109.178B
Beta0.78
PE Ratio (TTM)10.41
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.64 (3.79%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Sanofi's Pointeau on China Strategy, Partnerships
    Bloomberg Video5 days ago

    Sanofi's Pointeau on China Strategy, Partnerships

    Dec.07 -- Jean-Christophe Pointeau, China country chair at Sanofi, discusses the changes in the Chinese health market, his business strategy in China, his partnerships and the automation of the industry. He speaks on "Bloomberg Markets: Asia" from the Fortune Global Forum in Guangzhou.

  • Philippines shuts down sale of 'risky' dengue vaccine
    Reuters Videos7 days ago

    Philippines shuts down sale of 'risky' dengue vaccine

    A public health scandal escalates in the Philippines. Manila is halting the sale of Dengvaxia after a warning that the dengue vaccine might not be safe. Reuters' Eve Johnson reports on who is now finding themselves in the public crosshairs.

  • Philippines to probe Sanofi dengue vaccine
    Reuters Videos8 days ago

    Philippines to probe Sanofi dengue vaccine

    The Philippines orders a probe into the immunisation of more than 730,000 children with a vaccine for dengue that has been suspended following an announcement by French drug company Sanofi that it could worsen the disease in some cases. Silvia Antonioli reports.

  • Reuters11 hours ago

    FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes. Like Humalog, which earned Lilly $696.2 million in the latest quarter, the short-acting drug helps diabetics control blood sugar levels after eating.

  • Reuters12 hours ago

    FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. The drug is a short-acting ...

  • 3 High-Yield Dividend Stocks to Buy in 2018
    Motley Fool15 hours ago

    3 High-Yield Dividend Stocks to Buy in 2018

    These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.

  • Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?
    Zacks22 hours ago

    Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?

    Regeneron (REGN) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Sanofi Begins Combo Studies on Multiple Myeloma Candidate
    Zacks4 days ago

    Sanofi Begins Combo Studies on Multiple Myeloma Candidate

    Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.

  • Market Realist4 days ago

    How Eli Lilly’s Trajenta, Trulicity, and Basaglar Are Performing

    In 3Q17, Eli Lilly's (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis.

  • Philippines wants money back from Sanofi for dengue vaccine
    Associated Press4 days ago

    Philippines wants money back from Sanofi for dengue vaccine

    MANILA, Philippines (AP) — The Philippine government will demand a refund of 3.5 billion pesos ($69.5 million) from vaccine maker Sanofi Pasteur and look at possible legal action after a study showed the vaccine used in a dengue immunization program could expose some people to severe illness, the health chief said Friday.

  • Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz
    Zacks4 days ago

    Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz

    FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.

  • Reuters4 days ago

    Philippines to seek refund of $59 million from Sanofi amid vaccine risk

    The Philippines will seek the return of 3 billion pesos ($59 million) it paid French drugmaker Sanofi for a dengue vaccine used to immunise hundreds of thousands of children that Sanofi has said could worsen the disease in some cases. "We will demand the refund of the 3 billion (pesos) paid for the Dengvaxia and (demand) that Sanofi set up an indemnification fund to cover the hospitalisation and medical treatment of all children who might have severe dengue," Health Secretary Francisco Duque told reporters on Friday. The Philippines last week suspended a national immunisation programme after Sanofi's recent findings that there was a risk of severe dengue occurring in previously uninfected people who were inoculated with Dengvaxia.

  • Flu cases double as experts worry this season could be particularly bad
    CNBC5 days ago

    Flu cases double as experts worry this season could be particularly bad

    Experts worry this year's flu shot may not be as effective as it usually is.

  • Reuters7 days ago

    France advised against Sanofi's dengue drug for its territories

    A public body close to France's health ministry last year advised against the use of a dengue vaccine in the country's overseas territories that is currently at the centre of a health scare, regulatory documents show. Concerns surrounding the vaccine, sold by French drugmaker Sanofi under the brand Dengvaxia, have prompted the Philippines to halt its sale and suspend a government programme to immunise hundreds of thousands of children.

  • Sanofi's Toujeo Meets Key Objective in Head-to-Head Study
    Zacks7 days ago

    Sanofi's Toujeo Meets Key Objective in Head-to-Head Study

    Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.

  • Reuters7 days ago

    Severe dengue vaccine risk in uninfected '2 in a 1,000' -Sanofi

    French drugmaker Sanofi said on Tuesday the risk of severe dengue occurring in previously uninfected people given its Dengvaxia dengue vaccine was around two in 1,000 and these individuals recovered with treatment. The vaccine is at a centre of a safety row after new data showed it could worsen dengue in some cases, prompting the Philippines to halt its sale and suspend a government programme to immunise hundreds of thousands of children. Answering criticism about delays in reporting problems, Sanofi said it had only been able to conduct a detailed analysis to determine the impact of previous dengue infection this year, after co-developing a new assay with the University of Pittsburgh.

  • Reuters7 days ago

    Trial results of Zika vaccine Sanofi dropped show promise

    A Zika vaccine Sanofi SA dropped in September under political pressure over pricing produced strong responses in more than 90 percent of those taking part in an early-stage clinical trial, U.S. researchers reported on Monday. In February 2016, the World Health Organization declared the Zika outbreak in Brazil and elsewhere an international public health emergency because of the link between the virus and severe birth defects, touching off a scramble for a vaccine. The ZPIV vaccine, made from inactivated Zika virus particles, was developed by U.S. Army researchers, who in July 2016 had agreed to give Sanofi an exclusive license to complete testing and bring the product to market.

  • Reuters7 days ago

    Trouble mounts for Sanofi dengue vaccine over safety concerns

    The World Health Organization said on Monday it hopes to review safety data on Sanofi's dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization program after the French drugmaker said it could actually worsen the disease in some cases. The safety fears involve possible increased risk to people who had not previously been exposed to the dengue virus prior to vaccination with Dengvaxia. Dengvaxia, the first approved Dengue vaccine, had been forecast by Sanofi to eventually bring in nearly $1 billion in annual sales.

  • Amgen, Regeneron Prep For Battle In 2018 Over Cholesterol Drugs
    Investor's Business Daily7 days ago

    Amgen, Regeneron Prep For Battle In 2018 Over Cholesterol Drugs

    Amgen and Regeneron will battle in 2018 after the latter unveils cardiovascular data for its cholesterol drug Praluent.

  • The Wall Street Journal7 days ago

    [$$] Philippines Suspends Troubled Dengue Drug After More Than 730,000 Immunized

    The Philippines suspended a dengue fever vaccine that was given to thousands of children and launched an investigation, after the drug’s manufacturer said new evidence showed it could worsen symptoms in ...

  • Market Realist7 days ago

    Analysts’ Recommendations for Regeneron

    In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety ...

  • Reuters8 days ago

    Sanofi says monitoring outcomes of ongoing dengue vaccination schemes

    Sanofi (SASY.PA) on Monday said it was monitoring outcomes of ongoing public programs involving its dengue vaccine, Dengvaxia, following the launch of a probe in the Philippines. The Philippines ordered an investigation into the immunization of more than 730,000 children with the French drugmaker's product after Sanofi said last week the vaccine should not be recommended for individuals who have not been previously infected by the virus. "It is important to note that the vast majority of those vaccinated to date live in high endemic settings and, therefore, will have had a prior dengue infection before vaccination,", Sanofi said in an emailed statement.

  • Philippines orders probe into Sanofi dengue vaccine for 730,000 children
    Reuters8 days ago

    Philippines orders probe into Sanofi dengue vaccine for 730,000 children

    The Philippines ordered an investigation on Monday into the immunization of more than 730,000 children with a vaccine for dengue that has been suspended following an announcement by French drug company Sanofi (SASY.PA) that it could worsen the disease in some cases. The World Health Organization said it hoped to conduct a full review by year-end of data on the vaccine, commercially known as Dengvaxia. In the meantime, the WHO recommended that it only be used in people who had a prior infection with dengue.

  • Market Realist8 days ago

    How Regeneron Pharmaceuticals Performed in 3Q17

    In 3Q17, Regeneron Pharmaceuticals (REGN) generated revenue of $1.5 billion, which reflected ~23% growth year-over-year and ~2% growth quarter-over-quarter.

  • Reuters8 days ago

    Brazil recommends restrictions on Sanofi dengue vaccine

    The Brazilian government said on Monday it has suggested restrictions on the use of a dengue vaccine that has been suspended elsewhere after French drug company Sanofi SA said it could worsen the disease in some cases. Brazil's healthcare regulator Anvisa said it is now recommending that people who have never been infected with dengue not take the vaccine, which was approved for use in Brazil at the end of 2015. The Brazilian government has not suspended the drug entirely, although the Philippine government has.